Related Experiment Video
Updated: Jul 10, 2026

Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: December 22, 2020
Targeting of phospholamban by peroxynitrite decreases beta-adrenergic stimulation in cardiomyocytes
Mark J Kohr1, Honglan Wang, Debra G Wheeler
1Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA.
Aims:
Peroxynitrite production increases during the pathogenesis of numerous cardiac disorders (e.g. heart failure). However, limited studies have investigated the mechanism through which peroxynitrite exerts anti-adrenergic effects. Thus, the purpose of this study is to investigate the contribution of phospholamban (PLB), a critical excitation-contraction coupling protein, to the peroxynitrite-induced dysfunction.
Methods And Results:
Isolated myocytes from wild-type (WT, CF-1) and PLB knockout (PLB(-/-)) mice were stimulated at 1 Hz, and myocyte shortening and Ca(2+) transients were simultaneously recorded. PLB phosphorylation was measured via western blot. Myocytes were superfused with isoproterenol, a beta-adrenergic agonist, and SIN-1, a peroxynitrite donor. SIN-1 superfusion dramatically decreased isoproterenol-stimulated Ca(2+) transients and myocyte shortening in WT myocytes. These effects were inhibited upon addition of the peroxynitrite decomposition catalyst, FeTPPS. Surprisingly, SIN-1 had no functional effect on beta-adrenergic-stimulated PLB(-/-) myocytes. Western blot analyses revealed that SIN-1 significantly decreased isoproterenol-stimulated PLB(Ser16) phosphorylation. Experiments with the protein phosphatase inhibitor, okadaic acid, alleviated the SIN-1-induced functional effects and the decrease in PLB phosphorylation.
Conclusions:
The peroxynitrite donor SIN-1 decreases beta-adrenergic stimulation by reducing PLB(Ser16) phosphorylation via protein phosphatase activation. This peroxynitrite-induced decrease in PLB phosphorylation may be a key mechanism in the beta-adrenergic dysfunction observed in many cardiomyopathies.
Insights
Peroxynitrite impairs cardiac beta-adrenergic function by reducing phospholamban (PLB) phosphorylation, a key mechanism in heart failure. This study reveals PLB
Area of Science:
- Cardiovascular Physiology
- Cardiac Pathophysiology
- Molecular Cardiology
Background:
- Peroxynitrite is implicated in cardiac disorders like heart failure.
- The mechanisms underlying peroxynitrite's anti-adrenergic effects are not fully understood.
- Phospholamban (PLB) is crucial for cardiac excitation-contraction coupling.
Purpose of the Study:
- To investigate phospholamban's role in peroxynitrite-induced cardiac dysfunction.
- To elucidate the mechanism by which peroxynitrite affects beta-adrenergic signaling.
Main Methods:
- Isolated cardiomyocytes from wild-type and PLB knockout mice were used.
- Myocyte shortening and calcium transients were measured under beta-adrenergic stimulation.
- Peroxynitrite donor (SIN-1) and phospholamban phosphorylation were analyzed.
Main Results:
- Peroxynitrite significantly reduced beta-adrenergic-stimulated myocyte function and Ca(2+) transients in wild-type but not PLB knockout myocytes.
- Peroxynitrite decreased phospholamban phosphorylation at Ser16.
- Inhibition of protein phosphatases reversed the functional effects of peroxynitrite.
Conclusions:
- Peroxynitrite impairs cardiac beta-adrenergic responsiveness by reducing phospholamban phosphorylation via protein phosphatase activation.
- This mechanism may contribute to beta-adrenergic dysfunction in cardiomyopathies.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Nitric Oxide Signaling Pathway
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
